Compare BLTE & ROAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | ROAD |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.7B |
| IPO Year | 2021 | 2018 |
| Metric | BLTE | ROAD |
|---|---|---|
| Price | $158.49 | $123.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $198.00 | $127.80 |
| AVG Volume (30 Days) | 117.4K | ★ 405.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.46 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $785,679,000.00 |
| Revenue This Year | N/A | $27.79 |
| Revenue Next Year | $492.11 | $10.29 |
| P/E Ratio | ★ N/A | $372.90 |
| Revenue Growth | N/A | ★ 0.31 |
| 52 Week Low | $56.68 | $86.70 |
| 52 Week High | $200.00 | $141.90 |
| Indicator | BLTE | ROAD |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 55.96 |
| Support Level | $157.63 | $105.38 |
| Resistance Level | $161.28 | $126.98 |
| Average True Range (ATR) | 6.26 | 5.50 |
| MACD | -1.15 | 0.37 |
| Stochastic Oscillator | 17.27 | 69.07 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.